stockrowFortrea Holdings Inc.
FTRE Healthcare Biotechnology
Fortrea Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 1.00% from fiscal 2024.
- Revenue
- −1.40%
- EPS
- +103.7%
- Free cash flow
- −34.0%
- Total debt
- −6.33%
Quarter to September 2026, against a year earlier
Follow FTRE
Alert me
Fortrea Holdings Inc. (FTRE) Total debt
Fortrea Holdings Inc.'s total debt at the end of fiscal 2025 was $1.1B, down 6.38% from $1.1B in fiscal 2024. At the end of the quarter to 30 September 2026 it was $1.1B. Over the past ten years it has ranged from $63.0M (fiscal 2022) to $1.6B (fiscal 2023); the current reading is higher than 60% of that period. Fortrea Holdings Inc. ranks 14th of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $1.1B | (6.38%) |
| FY2024 | $1.1B | (29.37%) |
| FY2023 | $1.6B | 2,426.98% |
| FY2022 | $63.0M | (18.18%) |
| FY2021 | $77.0M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $1.1B | 0.09% |
| Jun 2026 | $1.1B | 0.08% |
| Mar 2026 | $1.1B | 0.07% |
| Dec 2025 | $1.1B | (6.55%) |
| 11 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| FTRE Fortrea Holdings Inc. | $1.1B |
| SRPT Sarepta Therapeutics, Inc. compare | $857.4M |
| BHVN Biohaven Ltd. compare | $264.3M |
| HRMY Harmony Biosciences Holdings, Inc. compare | $149.1M |
| VIR Vir Biotechnology, Inc. compare | $128.0M |
| REPL Replimune Group, Inc. compare | $121.2M |
| ZYME Zymeworks Inc. compare | $278.0K |
| IMNM Immunome, Inc. compare | $228.0K |
| TRAX First Tracks Biotherapeutics, Inc. compare | — |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt